Biogen Inc is planning to file for U.S. regulatory approval for its Alzheimer's treatment aducanumab after fresh analysis of its clinical trial showed promise, the drugmaker said on Tuesday, sending its shares up 21per cent before the bell.
Share this content
REUTERS: Biogen Inc revealed surprise plans to seek U.S. regulatory approval for its Alzheimer's treatment aducanumab on Tuesday, saying new analysis of clinical trials showed promise, just months after it had shelved two studies.
The drugmaker's shares, which has been under pressure from investors to beef up its drug development pipeline and also reported a better-than-expected third quarter profit, soared 35per cent, more than erasing all of its losses so far this year.
Biogen and partner Eisai Co Ltd had in March decided to end two late-stage trials of aducanumab based on a so-called "futility analysis" of data, which revealed the trials had little hope of succeeding.
The failure of treatment, which was widely expected to be the Biogen's next blockbuster treatment, spurred demands on Wall Street for it to spend more on product acquisitions at a time when its peers have splurged out billions of dollars on deals.
There are no current approved therapies for reversing the decline of Alzheimer's and any successful new treatment is likely to garner billions in sales. Alzheimer's makes up 60-70per cent of an estimated 50 million cases of dementia globally.
The company said more data became available after the two studies that were discontinued in March, resulting in a larger dataset and a new analysis showed a positive outcome for the trial.
Patients who received aducanumab experienced significant benefits on measures of cognition and function such as memory, orientation and language, Biogen said.
The filing with U.S. regulators could "potentially bring back to life a drug that had been completely left for dead," RBCRead More – Source